The natural history of carbapenemase-producing Enterobacterales: progression from carriage of various carbapenemases to bloodstream infection.
carbapenemase
antibiotic resistance
bloodstream infection
carbapenem-resistant Enterobacterales
epidemiology
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 Mar 2024
06 Mar 2024
Historique:
received:
29
09
2023
revised:
11
01
2024
accepted:
16
01
2024
medline:
7
3
2024
pubmed:
7
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
Little is known about the risk of progression from carbapenemase-producing Enterobacterales (CPE) carriage to CPE bloodstream infection (BSI) outside of high-risk settings. We aimed to determine the incidence of CPE BSI among CPE carriers and to assess whether the incidence differed by carbapenemase, species, and setting. We conducted a nationwide population-based retrospective cohort study using national databases. The cohort consisted of all patients in Israel with CPE detected by screening from 1/1/2020 to 10/10/2022. We calculated the cumulative incidence of CPE BSI within 1 year among CPE carriers. We used a competing-risks model with BSI as the outcome and death as the competing risk. The study included 6,828 CPE carriers. The cumulative incidence of CPE BSI was 2.4% (95% CI: 2.1%-2.8%). Compared to KPC, the subhazard of BSI was lower for NDM (aSHR: 0.72, 95% CI: 0.49-1.05) and OXA-48-like (aSHR: 0.60, 95% CI: 0.32-1.12) but these differences did not reach statistical significance. Compared to K. pneumoniae, the subhazard of BSI was lower for carriers of carbapenemase-producing E. coli (aSHR: 0.31, 95% CI: 0.20-0.47). The subhazard of BSI was higher among patients with CPE carriage first detected in intensive care units (aSHR: 2.42, 95% CI: 1.50-3.92) or oncology/hematology wards (aSHR: 3.77, 95% CI: 2.40-5.93) compared to medical wards. The risk of CPE BSI among CPE carriers is lower than previously reported in studies that focused on high-risk patients and settings. The risk of BSI differs significantly by bacterial species and setting, but not by carbapenemase.
Sections du résumé
BACKGROUND
BACKGROUND
Little is known about the risk of progression from carbapenemase-producing Enterobacterales (CPE) carriage to CPE bloodstream infection (BSI) outside of high-risk settings. We aimed to determine the incidence of CPE BSI among CPE carriers and to assess whether the incidence differed by carbapenemase, species, and setting.
METHODS
METHODS
We conducted a nationwide population-based retrospective cohort study using national databases. The cohort consisted of all patients in Israel with CPE detected by screening from 1/1/2020 to 10/10/2022. We calculated the cumulative incidence of CPE BSI within 1 year among CPE carriers. We used a competing-risks model with BSI as the outcome and death as the competing risk.
RESULTS
RESULTS
The study included 6,828 CPE carriers. The cumulative incidence of CPE BSI was 2.4% (95% CI: 2.1%-2.8%). Compared to KPC, the subhazard of BSI was lower for NDM (aSHR: 0.72, 95% CI: 0.49-1.05) and OXA-48-like (aSHR: 0.60, 95% CI: 0.32-1.12) but these differences did not reach statistical significance. Compared to K. pneumoniae, the subhazard of BSI was lower for carriers of carbapenemase-producing E. coli (aSHR: 0.31, 95% CI: 0.20-0.47). The subhazard of BSI was higher among patients with CPE carriage first detected in intensive care units (aSHR: 2.42, 95% CI: 1.50-3.92) or oncology/hematology wards (aSHR: 3.77, 95% CI: 2.40-5.93) compared to medical wards.
CONCLUSIONS
CONCLUSIONS
The risk of CPE BSI among CPE carriers is lower than previously reported in studies that focused on high-risk patients and settings. The risk of BSI differs significantly by bacterial species and setting, but not by carbapenemase.
Identifiants
pubmed: 38447961
pii: 7623571
doi: 10.1093/cid/ciae110
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Tal Brosh-Nissimov
(T)
Maya Katz
(M)
Nadav Sorek
(N)
Ali Sabateen
(A)
Bina Rubinovitch
(B)
Rana Shbita Shaaban
(RS)
Zhanna Shor
(Z)
Mirit Hershman-Sarafov
(M)
Tamar Boumard
(T)
Ronza Najjar-Debbiny
(R)
Gabriel Weber
(G)
Tal Bendahan
(T)
Ayelet Favor
(A)
Ilana Gross
(I)
Jana Hen
(J)
Ayelet Michael-Gayego
(A)
Yonatan Oster
(Y)
Miriam Ottolenghi
(M)
Nechamat Reichman
(N)
Naama Ronen
(N)
Nehama Shilo
(N)
Violeta Temper
(V)
Bibiana Chazan
(B)
Iris Grinberg Abraham
(IG)
Regev Cohen
(R)
Rita Bardenstein
(R)
Pnina Ciobotaro
(P)
Maly Oved
(M)
Hadar Klorfeld
(H)
Pnina Shitrit
(P)
Alia Yassin
(A)
Amir Nutman
(A)
Vered Schechner
(V)
Worood Aboalhega
(W)
Khetam Hussein
(K)
Dina Pollak
(D)
Sigal Warman
(S)
Meirav Mor
(M)
Sigalit Rozenfeld
(S)
Marc Assous
(M)
Shmuel Benenson
(S)
Liora Bier
(L)
Puah Kopuit
(P)
Ameen Jaraisy
(A)
Nili Nimri
(N)
Jalal Abu Hanna
(JA)
Sarit Stepansky
(S)
Debby Ben-David
(D)
Yael Cohen
(Y)
Orna Schwartz
(O)
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.